Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Sarcoma 54Lymphoma 40Lymphoma, Large B-Cell, Diffuse 28Lymphoma, Non-Hodgkin 21Hodgkin Disease 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Osteosarcoma 17Testicular Neoplasms 15Burkitt Lymphoma 15Leukemia 14Lymphoma, Large-Cell, Immunoblastic 13Lymphoma, Follicular 13Ovarian Neoplasms 12Lymphoma, Mantle-Cell 12Neuroectodermal Tumors, Primitive, Peripheral 11Testicular Germ Cell Tumor 10Liposarcoma 10Histiocytoma, Malignant Fibrous 10Hemangiosarcoma 10Fibrosarcoma 10Sarcoma, Synovial 9Rhabdomyosarcoma 9Neurofibrosarcoma 9Lymphoma, Large-Cell, Anaplastic 9Leiomyosarcoma 9Teratoma 8Recurrence 8Neuroblastoma 8Lymphoma, B-Cell, Marginal Zone 8Leukemia, Lymphocytic, Chronic, B-Cell 8

Interventions

dacetuzumab 5blinatumomab 4Bortezomib 4Lenalidomide 3Dexamethasone 3Rituximab 2tetulomab tetraxetan lu-177 1ponatinib 1pembrolizumab 1pegaspargase 1isatuximab 1ibrutinib 1ficlatuzumab 1durvalumab 1asparaginase erwinia chrysanthemi recombinant 1acalabrutinib 1Vorinostat 1Methotrexate 1Lutetium 1KW-2478 1Ifosfamide 1Hsp90 inhibitor KU757 1Gemcitabine 1Erlotinib Hydrochloride 1Daunorubicin 1Cyclophosphamide 1Calcium Dobesilate 1Brentuximab Vedotin 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Immunoproliferative Disorders × Ifosfamide × Clear all
NCT02393859 2024-05-29

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Amgen

Phase 3 Completed
111 enrolled 23 charts 1 FDA
LymphoidOther hematologic neoplasm

Immunoproliferative Disorders, Lymphoproliferative Disorders, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡